THEMATIC REVIEW

Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors

Samuel A Wells Jr

Genetics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Correspondence should be addressed to S A Wells: wellss@mail.nih.govThis paper is part of a thematic review section on 25 Years of *RET* and MEN2. The guest editors for this section were Lois Mulligan and Frank Weber.

Abstract

Medullary thyroid carcinoma (MTC), a tumor derived from the neural crest, occurs either sporadically or as the dominant component of the type 2 multiple endocrine neoplasia (MEN) syndromes, MEN2A and MEN2B. The discovery that mutations in the *RET* protooncogene cause hereditary MTC was of great importance, since it led to the development of novel methods of diagnosis and treatment. For example, the detection of a mutated *RET* allele in family members at risk for inheriting MEN2A or MEN2B signaled that they would develop MTC, and possibly other components of the syndromes. Furthermore, the detection of a mutated allele created the opportunity, especially in young children, to remove the thyroid before MTC developed, or while it was confined to the gland. The discovery also led to the development of molecular targeted therapeutics (MTTs), mainly tyrosine kinase inhibitors, which were effective in the treatment of patients with locally advanced or metastatic MTC. While responses to MTTs are often dramatic, they are highly variable, and almost always transient, because the tumor cells become resistant to the drugs. Clinical investigators and the pharmaceutical industry are focusing on the development of the next generation of MTTs, which have minimal toxicity and greater specificity for mutated *RET*.

Key Words

- ▶ MEN2
- ▶ medullary thyroid carcinoma

Endocrine-Related Cancer
(2018) **25**, T1–T13

Introduction

The description of MEN2A is often attributed to Sipple, who in 1961 reported a patient with a pheochromocytoma (PHEO) and cancer of the thyroid gland (Sipple 1961). In reviewing the literature, he found 537 reports of PHEO and 27 associated malignancies, 6 of which were thyroid cancers. The thyroid cancer in Sipple's patient was described as a poorly differentiated follicular adenocarcinoma, which is understandable, considering that the publication describing medullary thyroid carcinoma (MTC) occurred only 18 months earlier, and many pathologists were

unaware of it (Hazard *et al.* 1959). Also, it would be another 7 years before Steiner and coworkers described a family with MTC, PHEO, hyperparathyroidism (HPTH) and Cushing's syndrome (Steiner *et al.* 1968). They suggested that 'the entity characterized by tumors of the pituitary, parathyroids and pancreas be designated as multiple endocrine neoplasia (MEN) type 1, and that the entity characterized by the occurrence of PHEO, MTC and parathyroid tumors be designated as MEN type 2' (Wermer 1954, Steiner *et al.* 1968). Therefore, the first publication

describing MEN2A was clearly that of Steiner and coworkers, although earlier publications, including that of Sipple (and the subsequent report that the relatives of his patient had MEN2A), were evidence that the syndrome had existed for some time, but was not recognized as such (Sipple 1961, 1984, Telenius-Berg *et al.* 1984, Hughes 1996, Neumann *et al.* 2007). In 1966 two years prior to Steiner's report, Williams and Pollack described 2 patients with MTC, PHEOs, ganglioneuromatosis of the aerodigestive tract and an unusual physical appearance (Williams & Pollock 1966). The syndrome was thought to be allied to von Recklinghausen's disease, but it was recognized subsequently as being similar to MEN2A and was named MEN2B. Farndon and coworkers described familial medullary thyroid carcinoma (FMTC), a syndrome distinguished by the presence of hereditary MTC, but none of the extrathyroidal manifestations of MEN2A (Farndon *et al.* 1986). As additional families were studied over subsequent decades, investigators concluded that FMTC was a variant of MEN2A (Wells *et al.* 2015). Two other conditions occasionally occur in association with MEN2A: cutaneous lichen amyloidosis (CLA) and Hirschsprung's disease (HD) (Gagel *et al.* 1989, Nunziata *et al.* 1989, Sijmons *et al.* 1998, Amiel *et al.* 2008).

The American Thyroid Association's Task Force to revise the management guidelines for MTC proposed 4 variants of MEN2A: classical MEN2A, characterized by MTC, PHEOs and HPTH; MEN2A and CLA; MEN2A and HD; and FMTC (Wells *et al.* 2015). Classical MEN2A is characterized by complete penetrance but variable expressivity in that virtually all patients develop MTC, but PHEOs and HPTH occur less frequently, often depending on the presence of a specific *RET* codon mutation. Also, MEN2A and CLA, and MEN2A and HD are almost always associated with specific *RET* codon mutations. The presentation of MEN2B is more uniform in that all patients develop MTC, ganglioneuromatosis and the typical phenotype, and more than 60% develop PHEOs. Generally, the MTC in patients with MEN2B is more aggressive clinically compared to the MTC in patients with MEN2A.

MTC is derived from the thyroid C-cells, which secrete the peptide calcitonin (CTN), and the glycoprotein, carcinoembryonic antigen (CEA). Measurement of serum CTN levels is especially useful in the timing of thyroidectomy in patients who have inherited a mutated *RET* allele, and in the evaluation of patients following thyroidectomy. The calculation of the time it takes for serum levels of CTN to double provides a reliable index of the rate of tumor growth, and thereby patient prognosis.

The molecular basis of the MEN2 syndromes

The MEN2 variants and MEN2B are inherited in an autosomal dominant pattern, and each is caused by germline mutations in the *RET* (rearranged during transfection) protooncogene (Donis-Keller *et al.* 1993, Mulligan *et al.* 1993). *RET* spans 21 exons on chromosome 10 (10q11.2) and encodes a highly conserved single-pass transmembrane receptor of the tyrosine kinase family. The gene is expressed in cells derived from the neural crest: the brain, parasympathetic and sympathetic ganglia, the thyroid C-cells, the adrenal medulla and the urogenital tract (Nakamura *et al.* 1994).

Characterization of MEN2A

Classical MEN2A is the most common MEN2A variant, and 95% of the patients have *RET* mutations in codons 609, 611, 618 or 620 of exon 10, or codon 634 of exon 11. In patients with *RET* mutations in codon C634, the MTC has an earlier age of onset, and a more aggressive clinical course, compared to that in patients with *RET* mutations in codons other than C634. If an MTC is more aggressive than that expected with a specific *RET* codon mutation, it is important to completely sequence the tumor DNA, since a second *RET* codon mutation may be the reason for the MTC's unexpected behavior (Cerutti & Maciel 2013).

In patients with *RET* C634 codon mutations, the incidence of PHEO is 50% by the 5th decade and approaches 90% by the 8th decade (Imai *et al.* 2013). In patients with *RET* codon mutations, other than C634, the incidence of PHEOs ranges from 4% to 25% (Table 1). Prior to the advent of genetic screening in families with MEN2A, the most common cause of death was PHEOs not MTC (Lips *et al.* 1995). HPTH occurs in about 30% of the patients with MEN2A and *RET* 634 codon mutations, and is less frequent in patients with mutations in other *RET* codons (Table 1).

In MEN2A and CLA, the CLA is manifested by the presence of a skin lesion in the scapular region of the back, corresponding to dermatomes T2–T6. The CLA almost always occurs in patients with an *RET* 634 codon mutation, although there have been reports of CLA in patients with an *RET* V804 codon mutation, and an *RET* S891A codon mutation (Gagel *et al.* 1989, Rothberg *et al.* 2009, Qi *et al.* 2015, Scapineli *et al.* 2016). Originally, CLA was thought to be uncommon, but it has been reported to occur in 35% of the patients with an *RET* 634 codon mutation (Verga *et al.* 2003). Patients may be

Table 1 Relationship of common *RET* mutations to risk of aggressive MTC in MEN2A and MEN2B, and to the incidence of PHEO, HPTH, CLA and HD in MEN2A. Reproduced, with permission, from Wells *et al.* (2015). Copyright 2015 American Thyroid Association and Mary Ann Liebert Inc.

<i>RET</i> mutation	Exon	MTC risk level ^a	Incidence of PHEO ^b	Incidence of HPTH ^b	CLA ^c	HD ^c
G533C	8	MOD	+	-	N	N
C609F/G/R/S/Y	10	MOD	+/++	+	N	Y
C611F/G/S/Y/W	10	MOD	+/++	+	N	Y
C618F/R/S	10	MOD	+/++	+	N	Y
CF20F/R/S	10	MOD	+/++	+	N	Y
C630R/Y	11	MOD	+/++	+	N	N
D631Y	11	MOD	+++	-	N	N
C634F/G/R/S/W/Y	11	H	+++	++	Y	N
K666E	11	MOD	+	-	N	N
E768D	13	MOD	-	-	N	N
L790F	13	MOD	+	-	N	N
V804L	14	MOD	+	+	N	N
V804M	14	MOD	+	+	Y	N
A883F	15	H	+++	-	N	N
S891A	15	MOD	+	+	N	N
R912P	16	MOD	-	-	N	N
M918T	16	HST	+++	-	N	N

^aRisk of aggressive MTC: MOD, moderate; H, high; HST, highest; MTC, medullary thyroid carcinoma; PHEO, pheochromocytoma; HPTH, hyperparathyroidism; CLA, cutaneous lichen amyloidosis; HD, Hirschsprung's disease; ^bincidence of PHEO and HPTH; ^cY, positive occurrence; N, negative occurrence: +=~10%, ++=~20–30%, +++=~5–10%.

asymptomatic, but most of them complain of localized pruritus and persistent scratching that result in thickened hyperpigmented skin. In youngsters, the CLA may precede clinical evidence of MEN2A, and thereby serve as a marker for the presence of a mutated *RET* allele, and the impending development of MTC.

HD occurs in approximately 7% of the patients with MEN2A; conversely, 2–5% of the patients with HD have MEN2A (Decker & Peacock 1998, Sijmons *et al.* 1998). In MEN2A and HD, the HD occurs in patients with *RET* codon mutations in exon 10: 609 (15%), 611 (5%), 618 (30%) and 620 (50%) (Mulligan *et al.* 1994, Borst *et al.* 1995). *RET* mutations also occur in approximately 50% of the patients with hereditary HD, and in 20%–33% of the patients with sporadic HD (Romeo *et al.* 1994, Amiel *et al.* 2008). The *RET* mutations in HD are 'loss of function' mutations that disable RET activation, whereas the *RET* mutations in MEN2A are 'gain of function' mutations that induce constitutive activation of RET. It seems paradoxical that HD should develop in patients with MEN2A; the explanation being that the *RET* mutations in exon 10 are sufficient to trigger neoplastic transformation of the thyroid C-cells and the adrenal chromaffin cells, but are insufficient to express the RET protein at the cell surface, resulting in a failed trophic response in precursor neurons (Asai *et al.* 2006). It is important to screen for MEN2A in patients with HD and to screen for HD in patients with MEN2A and exon 10 mutations.

FMTC, initially thought to be a stand-alone entity, different from MEN2A and MEN2B, is now considered a variant of MEN2A. Many families, classified as FMTC variants, move forthwith into the classical MEN2A category if a single family member develops a PHEO or HPTH (Oliveira *et al.* 2011).

Characterization of MEN2B

MEN2B accounts for 5% of the hereditary MTCs and is characterized by the presence of MTC, PHEOs, ganglioneuromatosis of the aerodigestive tract and a typical phenotype, consisting of a marfanoid habitus, typical facies and skeletal abnormalities. Over 75% of the cases of MEN2B are sporadic, the result of *de novo* *RET* mutations in a normal appearing parent-almost always the father (Carlson *et al.* 1994). The mean age at diagnosis is 14.2 years and despite the typical phenotype, patients often go unrecognized until the MTC has spread beyond the thyroid gland and is incurable. In families with hereditary MEN2B, the disease may be apparent at, or soon after birth, when thyroidectomy may be curative; however, the MTC is aggressive in this setting, and rare infants have regional lymph node metastases at the time of thyroidectomy (Zenaty *et al.* 2009). Approximately 95% of the patients with MEN2B have an *RET* M918T codon mutation, and the remainder have an *RET* A833F codon mutation

(Eng *et al.* 1994, Gimm *et al.* 1997) The MTC appears to be less aggressive in patients with the *RET* A833F codon mutation compared to the MTC in patients with an *RET* M918T codon mutation (Jasim *et al.* 2011).

Over 100 *RET* point mutations, duplications, insertions, deletions or fusions have been identified in patients with MEN2A, whereas only two *RET* mutations have been identified in patients with MEN2B (Wells *et al.* 2015). The most common *RET* mutations occurring in patients with MEN2A and MEN2B, the associated aggressiveness of the MTC and the frequency of the MEN2 variants, PHEOs and HPTH, are shown in Table 1.

Although *RET* mutations appear to be the sole driver in patients with the MEN2 syndromes, there are *RET* variants of unknown significance (VUS) that are neither benign polymorphisms nor active pathogenic mutations. Family members with the same VUS should be followed expectantly (Crockett *et al.* 2011).

Sporadic MTC

In 75% of the patients with MTC, the disease is sporadic arising from somatic *de novo* *RET* mutations. Approximately 40% of the patients have *RET* M918T codon mutations, and approximately 30% have *RAS* mutations, most often *KRAS* or *HRAS* (Moura *et al.* 2011, 2015). In patients with sporadic MTC, an *RET* M918T codon mutation is associated with a more aggressive clinical course, compared to that in patients with *RAS* mutations (Elisei *et al.* 2008). Genetic screening is important in patients with presumed sporadic MTC, since 7–15% of them will be found to have an *RET* germline mutation and hereditary MTC (Eng *et al.* 1995, Romei *et al.* 2011, Kihara *et al.* 2016).

Management of MTC

In families with MEN2A, it is critical to establish a genetic screening program to identify members who have inherited a mutated *RET* allele and offer them genetic counseling. In most kindreds with MEN2A, family members decide to have a thyroidectomy if they are found to have a mutated *RET* allele or clinical evidence of MTC. Some elderly patients who have an *RET* mutation do not wish to have a thyroidectomy, even if they have a thyroid nodule. Most adult members of families with MEN2A advise a thyroidectomy in their children, since it is the only cure for MTC, assuming that the tumor has not developed, or is confined to the thyroid gland. Even though the procedure is usually referred to as a prophylactic thyroidectomy, and indeed

a few patients have no evidence of a C-cell disorder in the thyroidectomy specimen, the majority of patients have C-cell hyperplasia, or small foci of MTC. Therefore, a better term for the procedure is early thyroidectomy.

Before the discovery of *RET* mutations in patients with MEN2A, the detection of an elevated serum calcitonin level served as the basis for timing thyroidectomy. Although this strategy was useful, the frequency of false positive values led to unnecessary operations (Marsh *et al.* 1996). Following the discovery of *RET* mutations as the cause of MEN2, oncologists based the timing of thyroidectomy largely on the presence of a specific *RET* codon mutation. There were also problems with this strategy, since there is substantial variability in the age at which MTC develops, not only among different families with the same *RET* codon mutation, but among individuals within the same family. Currently, the generally accepted practice is to use a combination of genetic testing and the basal or stimulated serum calcitonin level to decide the timing of thyroidectomy.

Generally, in patients with MEN2A, and an *RET* C634 codon mutation, the thyroid should be removed around 5 years of age. The surgeon can avoid dissecting the central zone of the neck, since lymph node metastases rarely occur by this age. When there is no central zone dissection, the parathyroid glands can be left *in situ* if they are normal in size, realizing that the patient may develop HPTH later in life. In the unusual situation where the parathyroid glands are enlarged, they can be managed by radical subtotal 3^{1/2} gland resection or total parathyroidectomy with heterotopic autotransplantation. Whatever the mode of management, it is important to preserve parathyroid function, since without it, the patient is committed to lifelong dependency on calcium and vitamin D replacement therapy, and is also vulnerable to the potential complications associated with chronic hypocalcemia.

Measurement of the serum calcitonin level, in the basal state or following stimulation with pentagastrin, or calcium, or both, is the most reliable way to detect persistent or residual MTC after thyroidectomy (Skinner *et al.* 2005). Some investigators consider that a basal serum calcitonin level within the normal range or a pentagastrin-stimulated serum calcitonin less than 10pg/mL following thyroidectomy represents a 'biochemical cure' (Barbot *et al.* 1994, Franc *et al.* 2001). A detectable basal postoperative serum CTN, even within the normal range, represents an incurable state, although the progression of the MTC is variable, and patients may go for years before they develop a clinical recurrence, if they ever

do. In one study, 50 consecutive youngsters with a germline *RET* mutation were evaluated at least 5 years after prophylactic thyroidectomy (Skinner *et al.* 2005). The basal and stimulated (with the combined intravenous infusion of pentagastrin and calcium) serum calcitonin levels were undetectable in 44 (88%) patients, but were elevated in 2 patients, one immediately postoperatively and the other at 3 years postoperatively. In 4 patients, the basal serum calcitonin levels were undetectable at every evaluation time point, but the stimulated calcitonin levels were above the normal range from 4 to 10 years after thyroidectomy (Fig. 1).

Prophylactic thyroidectomy, although extremely useful in youngsters, applies to a small number of patients with hereditary MTC, and no patients with sporadic MTC. In newly discovered families with MEN2A, one finds all stages of disease. In 75% of the patients with clinically evident thyroid nodules, the MTC has already spread to regional lymph nodes, and 10% of the patients have metastases at distant sites (Weber *et al.* 2001, Moley 2010). In some patients, even the elderly, the MTC is occult, the only evidence of its presence being an elevated serum calcitonin level. The management algorithm for patients found to have an *RET* germline mutation is shown in Fig. 2.

The preferred operation for most patients is total thyroidectomy with dissection of lymph nodes in the central neck. Additional lymph node compartments are dissected if there is evidence of metastases on preoperative imaging studies, or at the time of thyroidectomy.

Lifelong follow-up is indicated, beginning every three months postoperatively, and at longer intervals if there is no evidence of persistent or recurrent disease in the first year after thyroidectomy. Serial measurements of serum calcitonin and CEA levels are useful in documenting disease progression, and especially in the calculation of the time that it takes for the two markers to double. In a recent study of 65 patients, the 10-year survival was 8% in patients whose serum CTN doubling time was less than 6 months, 37% in patients with doubling times between 6 and 24 months and 96% in patients with doubling times greater than 24 months (Barbet *et al.* 2005). When the doubling times of serum CEA and serum calcitonin are concordant, the predictability of disease progression and prognosis is more accurate (Laure Giraudet *et al.* 2008).

Management of PHEO

Half or more of the patients with MEN2A and MEN2B develop PHEOs, the incidence increasing with age. The diagnosis of a PHEO succeeds the diagnosis of MTC in ~50% of the patients, is coterminous with the diagnosis of MTC in ~40% of the patients and precedes the diagnosis of MTC in ~10% of the patients (Rodriguez *et al.* 2008). The PHEOs are almost always benign, multicentric and confined to the adrenal gland (Modigliani *et al.* 1995). Regardless of whether the patient has MEN2A or MEN2B, it is critical to exclude the presence of a PHEO prior to any diagnostic or therapeutic intervention. Following resection

Figure 1

The results of 50 consecutive patients (mean age 10 years; range 3–19 years) who had inherited a mutated *RET* allele and were treated by prophylactic thyroidectomy. All patients were evaluated 5–10 years after surgery (mean 7 years) by physical examination and measurement of serum calcitonin levels following the combined administration of calcium and pentagastrin. Basal and stimulated serum calcitonin levels were undetectable in 44 patients, and they were considered cured. Basal serum calcitonin levels were undetectable in 4 patients but they increased above the normal range following stimulation 4–9 years after thyroidectomy. In two patients, basal and stimulated serum calcitonin levels were above the normal range, one immediately after thyroidectomy and the other not until 3 years after thyroidectomy. Data from Skinner *et al.* (2005).

Figure 2

Management of patients with an RET germline mutation detected on genetic screening. ATA, American Thyroid Association risk categories for aggressive medullary thyroid carcinoma (MTC) (HST, highest risk, H, high risk, MOD, moderate risk); Ctn, calcitonin; CEA, carcinoembryonic antigen; HPTH, hyperparathyroidism; PHEO, pheochromocytoma; RET, REarranged during Transfection; TTX, total thyroidectomy; US, ultrasound. Reproduced, with permission, from Wells *et al.* (2015). Copyright 2015 American Thyroid Association and Mary Ann Liebert Inc.

of one or more PHEOs, prolonged evaluation is important for two reasons. In the majority of patients, a contralateral PHEO will develop within 10 years after a unilateral adrenalectomy (Lairmore *et al.* 1993, Asari *et al.* 2006). Following a bilateral adrenalectomy, patients are at risk for an Addisonian crisis, especially if they become injured, or ill, or receive inadequate glucocorticoid replacement (Lairmore *et al.* 1993). Recognizing the complications associated with bilateral adrenalectomies, surgeons have recently turned to performing subtotal adrenalectomies in an attempt to preserve sufficient adrenal cortical tissue and obviate the need for glucocorticoid replacement, even under stressful conditions. Thus far, the experience has been mixed, as about half of the patients require supplemental glucocorticoids, and from 3% to 20% of the patients develop a recurrent PHEO at some time after surgery (Brauckhoff *et al.* 2008, Scholten *et al.* 2011, Brauckhoff & Dralle 2012). Cortical sparing adrenalectomy seems promising; however, long-term evaluation of many patients is necessary before the worth of the technique is established.

Management of HPTH

HPTH occurs in approximately 30% of the patients with MEN2A, most often in patients with RET mutations in exon 10 and exon 11, especially RET codon C634. The mean age at diagnosis is 33.7 years. The HPTH is usually mild and asymptomatic, but surgical resection is indicated if patients develop symptoms or signs related to hypercalcemic. The surgical options are either subtotal 3^{1/2} gland resection or total parathyroidectomy with a parathyroid autograft to a heterotopic site. The size of the individual parathyroid glands may vary, and the surgeon may be tempted to remove only those that are enlarged; however, this approach carries the risk that patients will develop persistent or recurrent HPTH. It is important that the surgeon identifies and marks the sites of parathyroid glands left *in situ* in order to identify them if the patient develops HPTH and requires reoperative surgery. The development of HPTH in patients who have had a prior thyroidectomy presents a challenge for the surgeon. Localization procedures, such as ultrasound, CT scans and

sestamibi scans, are useful to identify parathyroid glands prior to repeated exploration of the neck.

Management of patients with persistent or recurrent MTC

Patients who have a total thyroidectomy for MTC are evaluated at varying intervals by physical examination and laboratory tests, including measurement of serum levels of CTN and CEA. Imaging studies are indicated if the serum CTN level exceeds 150 pg/mL, or if there is clinical evidence of recurrent MTC. Repeat operations in patients with regional node metastases are rarely curative, and the treatment of patients with distant metastases is palliative (Scollo *et al.* 2003, Pelizzo *et al.* 2007, Wells *et al.* 2015).

In patients whose advanced MTC is not amenable to surgery, the treatment options are chemotherapy, a molecular targeted therapeutic (MTT) or continued observation (Fig. 3).

Chemotherapy

Formerly, either single agent or combination chemotherapy was front-line therapy for patients with advanced MTC; however, with most regimens, responses were infrequent and of short duration. Doxorubicin was the first chemotherapeutic that the FDA approved for the treatment of patients with advanced thyroid cancer, but it is seldom given alone, and is more often combined with either vindesine or cisplatin (Gottlieb *et al.* 1972,

Figure 3

Management of patients following thyroidectomy for persistent or recurrent medullary thyroid carcinoma. Ctn, calcitonin; CEA, carcinoembryonic antigen; EBRT, external beam radiotherapy; MTC, medullary thyroid carcinoma; TFTs, thyroid function tests; TSH, thyrotropin; TKI, tyrosine kinase inhibitor; TTX, total thyroidectomy; US, ultrasound. Reproduced, with permission, from Wells *et al.* (2015). Copyright 2015 American Thyroid Association and Mary Ann Liebert Inc.

Husain *et al.* 1978, Scherubl *et al.* 1990). The combined regimen of dacarbazine, vincristine and cyclophosphamide is moderately efficacy in patients with advanced MTC, and is currently the chemotherapeutic regimen of choice for patients with advanced MTC who have failed to respond to, or become resistant to, MTTs (Wu *et al.* 1994, Deutschbein *et al.* 2011, Tuttle *et al.* 2014).

External beam radiation (EBRT)

EBRT as adjuvant therapy is not indicated in patients with primary MTC, and is of little benefit in the treatment of patients with regional metastases, unless there is impending invasion of vital structures. EBRT is often palliative in patients with metastases to distant sites, such as brain or bone.

Molecular targeted therapeutics

In the normal state, external growth factors or ligands bind to cell surface receptor tyrosine kinases and transmit a series of intracellular signals. Mutations in these receptors lead to a state of constitutive activation with continuous signaling to the nucleus and immortalization of the cell. Recognizing that the mutated receptors are vulnerable targets, clinical investigators in collaboration with the pharmaceutical industry began to develop specific MTTs for patients with advanced malignancies. The first MTT to show efficacy in patients with a malignant disease (chronic myelogenous leukemia (CML)) was the tyrosine kinase inhibitor (TKI), gleevec (imatinib) (Druker *et al.* 2001). In a clinical trial of imatinib in patients with CML, there was, at 10.9 years, an overall survival of 83.3% and a complete cytogenetic remission of 82.8% (Hochhaus *et al.* 2017). The efficacy of imatinib in trials of patients with CML created great excitement among oncologists. Unfortunately, the experience with gleevec has not been replicated with various MTTs in patients with solid organ malignancies; however, in patients with advanced MTC, there have been encouraging results in clinical studies of 2 MTTs.

The first TKI approved by the FDA for any thyroid cancer was ZD6474, or vandetanib, an orally available anilinoquinazoline that in preclinical studies blocked the enzymatic activity of RET-derived oncoproteins at a one-half maximal inhibitory concentration of 100nM. Also in nude mice, ZD6474 blocked the formation of tumors derived from NIH-RET/PTC3 cells (Carlomagno *et al.* 2002). In a phase II trial of vandetanib in patients with locally advanced or metastatic MTC, the drug administered in a maximum tolerated dose of 300mg/day induced partial

remissions in 6 of the 30 patients, and disease stabilization in 22 patients. The estimated progression-free survival (PFS) was 27.9 months (Wells *et al.* 2010). Another trial of patients treated with vandetanib, 100mg/day, gave similar results (Robinson *et al.* 2010). Supported by the results of the phase II trials, investigators initiated a prospective, double-blind, randomized, phase III trial, evaluating the efficacy of vandetanib, compared to placebo in patients with advanced MTC (Wells *et al.* 2012). There was an estimated median PFS of 30.5 months in patients treated with vandetanib, compared to 19.3 months in patients receiving placebo (Table 2). Because of grade III adverse events, primarily diarrhea, rash, hypertension and headache, 35% of the patients required dose reductions. Based on results of the phase III trial, the FDA approved vandetanib for the treatment of patients with progressive, advanced metastatic MTC (Wells *et al.* 2012).

XL184, or cabozantinib, an orally available TKI with activity against MET, VEGFR2 and RET, prevented phosphorylation of target kinases, reduced cell growth and inhibited angiogenesis and tumor invasiveness in several cell lines (Yakes *et al.* 2011). In a phase I/II trial of cabozantinib in patients with advanced MTC, 29% had a partial remission and 68% had stable disease (Kurzrock *et al.* 2011). In a subsequent phase III prospective, double-blind, randomized trial of cabozantinib compared to placebo in patients with advanced MTC, the PFS in patients receiving cabozantinib was longer than that in patients receiving placebo (11.2 months compared to 4 months (Table 2). Grade 3 or 4 adverse events, including hemorrhage, fistulas and gastrointestinal perforation occurred in 69% of the patients treated with cabozantinib, and there were 9 deaths related to cabozantinib treatment. Based on the results of the phase III clinical trial, the FDA approved cabozantinib for the treatment of patients with advanced MTC (Elisei *et al.* 2013).

Other MTTs have shown efficacy in patients with advanced MTC, but none has been evaluated in phase III clinical trials (Table 2). Some of the compounds are used as second line therapy in patients who fail treatment with either vandetanib or cabozantinib. The agent most often used is sorafenib, a multikinase inhibitor, which has shown efficacy in phase I and phase II clinical trials of patients with MTC. The most common response has been disease stabilization (Lam *et al.* 2010, Capdevila *et al.* 2012).

The experience with MTTs in the treatment of patients with advanced MTC has been sobering. While vandetanib and cabozantinib have improved PFS, there has been no improvement in overall survival. Moreover,

Table 2 Clinical trials with molecular targeted therapeutics in patients with medullary thyroid carcinoma. Reproduced from Wells SA Jr, Pacini F, Robinson BG & Santoro M, Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update, *Journal of Clinical Endocrinology and Metabolism*, 2013, volume 98, pages 3149–3164, with permission from the Endocrine Society and Oxford University Press.

Drug (ref)	Study	No. pts.	PR (%)	SD (%)	PFS (mos.)
Axitinib (Cohen <i>et al.</i> 2008)	Phase II	11	18	27*	NA
Motesanib (Schlumberger <i>et al.</i> 2009)	Phase II	91	2	48**	12
Sorafenib (Lam <i>et al.</i> 2010)	Phase II	16	6.3	87.5*	17.9
Sunitinib (Ravaud <i>et al.</i> 2010)	Phase II	6	50	NA	NA
Vandetanib (Wells <i>et al.</i> 2010)	Phase II	30	20	53**	27.9#
Vandetanib (Robinson <i>et al.</i> 2010) (100mg/day)	Phase II	19	16	53**	NA
Cabozantinib (Kurzrock <i>et al.</i> 2011)	Phase II	37	29	41**	NA
Vandetanib (Wells <i>et al.</i> 2012)	Phase III	231/100	HR 0.46	0.46 (ORR)	30.5#
Cabozantinib (Elisei <i>et al.</i> 2013)	Phase III	219/111	HR 0.28	0.28 (ORR)	11.2#
Imatinib (de Groot <i>et al.</i> 2007)	Phase II	15	0	27**	0
Imatinib (Frank-Raue <i>et al.</i> 2007)	Phase II	9	0	56*	0
Sorafenib plus Tipifarnib (Hong <i>et al.</i> 2011)	Phase II	13	38	31**	17

*>4 mos; **>6 mos; #estimated PFS in months.

HR, hazard ratio comparing PFS in treated compared to placebo control patients; mos., months; NA, not available; No. pts., number of patients; ORR, overall response rate; PFS, progression-free survival; PR, partial response (RECIST); Ref, reference; SD, stable disease.

virtually all responses have been partial, not complete, and almost all patients become resistant to the therapy and develop progressive disease. For unknown reasons, the response to therapy can vary markedly, as noted in Fig. 4, which shows results of vandetanib treatment in 16 children with advanced MTC. Except for one child with sporadic MTC, all children had MEN2B and the M918T *RET* mutation, all received the same drug, and all of them looked alike; yet their responses to vandetanib varied from a ~10% to an ~80 reduction in tumor size. One would expect a similar response rate among the children in the study; yet the responses of the patients were no different from that seen in a more disparate patient population of adults with sporadic MTC, who were treated with vandetanib (Robinson *et al.* 2010, Wells *et al.* 2012).

Thus, the response to a given MTT is multifactorial and depends not only on the specific target mutation, and the treatment drug, but on unknown factors in the host. Considering the varied responses and the associated toxicities to the current MTTs used to treat patients with MTC, the pharmaceutical industry is concentrating on the development of MTTs that have minimal toxicity and a greater specificity for inhibiting mutated *RET*. Two such drugs (BLU-667 (NCT03037385); Blueprint Medicines, Inc., Cambridge, MA, USA) and (LOXO-292 (NCT03157128); Loxo Oncology, Stamford, CT, USA) are currently being evaluated in phase II clinical trials. The goal is to cure patients with advanced MTC, or at least convert their progressive disease to one that is chronic and longlasting.

Figure 4

A waterfall plot showing reduction in size of metastatic MTC in children with MEN2B who received vandetanib. Reproduced from Fox *et al.* (2013), with permission from the American Association for Cancer Research.

Declaration of interest

The author declares that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

References

- Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, Pelet A, Arnold S, Miao X, Griseri P, *et al.* 2008 Hirschsprung disease, associated syndromes and genetics: a review. *Journal of Medical Genetics* **45** 1–14. (<https://doi.org/10.1136/jmg.2007.053959>)
- Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichihara M, Murakumo Y & Takahashi M 2006 RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. *Pathology International* **56** 164–172. (<https://doi.org/10.1111/j.1440-1827.2006.01942.x>)
- Asari R, Scheuba C, Kaczirek K & Niederle B 2006 Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A. *Archives of Surgery* **141** 1199–1205. (<https://doi.org/10.1001/archsurg.141.12.1199>)
- Barbet J, Champion L, Kraeber-Bodere F, Chatal JF & Group GTES 2005 Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism* **90** 6077–6084. (<https://doi.org/10.1210/jc.2005-0044>)
- Barbot N, Calmettes C, Schuffenecker I, Saint-Andre JP, Franc B, Rohmer V, Jallet P & Bigorgne JC 1994 Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism* **78** 114–120.
- Borst MJ, VanCamp JM, Peacock ML & Decker RA 1995 Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. *Surgery* **117** 386–391. ([https://doi.org/10.1016/S0039-6060\(05\)80057-1](https://doi.org/10.1016/S0039-6060(05)80057-1))
- Brauckhoff M & Dralle H 2012 Function-preserving adrenalectomy for adrenal tumors. *Chirurg* **83** 519–527. (<https://doi.org/10.1007/s00104-011-2192-7>)
- Brauckhoff M, Stock K, Stock S, Lorenz K, Sekulla C, Brauckhoff K, Thanh PN, Gimm O, Spielmann RP & Dralle H 2008 Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. *World Journal of Surgery* **32** 863–872. (<https://doi.org/10.1007/s00268-007-9402-y>)
- Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, Corral J, Obiols G, Grande E, Grau JJ, *et al.* 2012 Sorafenib in metastatic thyroid cancer. *Endocrine-Related Cancer* **19** 209–216. (<https://doi.org/10.1530/ERC-11-0351>)
- Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A & Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. *Cancer Research* **62** 7284–7290.
- Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr & Goodfellow PJ 1994 Parent-of-origin effects in multiple endocrine neoplasia type 2B. *American Journal of Human Genetics* **55** 1076–1082.
- Cerutti JM & Maciel RM 2013 An unusual genotype-phenotype correlation in MEN 2 patients: should screening for RET double germline mutations be performed to avoid misleading diagnosis and treatment? *Clinical Endocrinology* **79** 591–592. (<https://doi.org/10.1111/cen.12155>)
- Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, *et al.* 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *Journal of Clinical Oncology* **26** 4708–4713. (<https://doi.org/10.1200/JCO.2007.15.9566>)
- Crockett DK, Piccolo SR, Ridge PG, Margraf RL, Lyon E, Williams MS & Mitchell JA 2011 Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene. *PLoS ONE* **6** e18380. (<https://doi.org/10.1371/journal.pone.0018380>)
- Decker RA & Peacock ML 1998 Occurrence of MEN 2a in familial Hirschsprung's disease: a new indication for genetic testing of the RET proto-oncogene. *Journal of Pediatric Surgery* **33** 207–214. ([https://doi.org/10.1016/S0022-3468\(98\)90433-X](https://doi.org/10.1016/S0022-3468(98)90433-X))
- Deutschbein T, Matuszczyk A, Moeller LC, Unger N, Yuce A, Lahner H, Mann K & Petersenn S 2011 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience. *Experimental and Clinical Endocrinology and Diabetes* **119** 540–543. (<https://doi.org/10.1055/s-0031-1279704>)
- Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P & Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. *Human Molecular Genetics* **2** 851–856. (<https://doi.org/10.1093/hmg/2.7.851>)
- Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, *et al.* 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. *New England Journal of Medicine* **344** 1031–1037. (<https://doi.org/10.1056/NEJM200104053441401>)
- Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, *et al.* 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. *Journal of Clinical Endocrinology and Metabolism* **93** 682–687. (<https://doi.org/10.1210/jc.2007-1714>)
- Elisei R, Schlumberger MJ, Muller SP, Schoffski P, Brose MS, Shah MH, Licita L, Jarzab B, Medvedev V, Kreissl MC, *et al.* 2013 Cabozantinib in progressive medullary thyroid cancer. *Journal of Clinical Oncology* **31** 3639–3646. (<https://doi.org/10.1200/JCO.2012.48.4659>)
- Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, Gardner E, Scheumann GF, Jackson CE, Tunnacliffe A, *et al.* 1994 Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. *Human Molecular Genetics* **3** 237–241. (<https://doi.org/10.1093/hmg/3.2.237>)
- Eng C, Mulligan LM, Smith DP, Healey CS, Frilling A, Raue F, Neumann HP, Ponder MA & Ponder SA 1995 Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. *Clinical Endocrinology* **43** 123–127. (<https://doi.org/10.1111/j.1365-2265.1995.tb01903.x>)
- Farnoud JR, Leight GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS & Wells SA Jr 1986 Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. *British Journal of Surgery* **73** 278–281. (<https://doi.org/10.1002/bjs.1800730411>)
- Fox E, Widemann BC, Chuk MK, Marcus L, Aikin A, Whitcomb PO, Merino MJ, Lodish M, Dombi E, Steinberg SM, *et al.* 2013 Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. *Clinical Cancer Research* **19** 4239–4248. (<https://doi.org/10.1158/1078-0432.CCR-13-0071>)
- Franc S, Niccoli-Sire P, Cohen R, Bardet S, Maes B, Murat A, Krivitzky A, Modigliani E & French Medullary Study G 2001 Complete surgical

- lymph node resection does not prevent authentic recurrences of medullary thyroid carcinoma. *Clinical Endocrinology* **55** 403–409. (<https://doi.org/10.1046/j.1365-2265.2001.01339.x>)
- Frank-Raue K, Fabel M, Delorme S, Haberkorn U & Raue F 2007 Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. *European Journal of Endocrinology* **157** 215–220. (<https://doi.org/10.1530/EJE-06-0695>)
- Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T & Tschen JA 1989 Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. *Annals of Internal Medicine* **111** 802–806. (<https://doi.org/10.7326/0003-4819-111-10-802>)
- Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM, Zajac JD, Robinson BG & Eng C 1997 Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. *Journal of Clinical Endocrinology and Metabolism* **82** 3902–3904. (<https://doi.org/10.1210/jcem.82.11.4508>)
- Gottlieb JA, Hill CS Jr, Ibanez ML & Clark RL 1972 Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. *Cancer* **30** 848–853. ([https://doi.org/10.1002/1097-0142\(197209\)30:3<848::AID-CNCR2820300336>3.0.CO;2-2](https://doi.org/10.1002/1097-0142(197209)30:3<848::AID-CNCR2820300336>3.0.CO;2-2))
- de Groot JW, Zonnenberg BA, van Ufford-Mannes PQ, de Vries MM, Links TP, Lips CJ & Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism* **92** 3466–3469. (<https://doi.org/10.1210/jc.2007-064>)
- Hazard JB, Hawk WA & Crile G Jr 1959 Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. *Journal of Clinical Endocrinology and Metabolism* **19** 152–161. (<https://doi.org/10.1210/jcem-19-1-152>)
- Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, *et al.* 2017 Long-term outcomes of imatinib treatment for chronic myeloid leukemia. *New England Journal of Medicine* **376** 917–927. (<https://doi.org/10.1056/NEJMoa1609324>)
- Hong DS, Cabanillas ME, Wheeler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, *et al.* 2011 Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multitargeted inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. *Journal of Clinical Endocrinology and Metabolism* **96** 997–1005. (<https://doi.org/10.1210/jc.2010-1899>)
- Hughes JMS, John H, Dougald C, MacGillivray, Howard R, Malchoff CD & Malchoff DM 1996 The Sipple syndrome: from clinical description genetic analysis in the index family. *Endocrinologist* **6** 427–430. (<https://doi.org/10.1097/00019616-199611000-00002>)
- Husain M, Alsever RN, Lock JP, George WF & Katz FH 1978 Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. *Hormone Research* **9** 22–25. (<https://doi.org/10.1159/000178893>)
- Imai T, Uchino S, Okamoto T, Suzuki S, Kosugi S, Kikumori T, Sakurai A & Japan MENCo 2013 High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. *European Journal of Endocrinology* **168** 683–687. (<https://doi.org/10.1530/EJE-12-1106>)
- Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C, Hu MI, Cote G & Habra MA 2011 Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. *Thyroid* **21** 189–192. (<https://doi.org/10.1089/thy.2010.0328>)
- Kihara M, Miyauchi A, Yoshioka K, Oda H, Nakayama A, Sasai H, Yabuta T, Masuoka H, Higashiyama T, Fukushima M, *et al.* 2016 Germline RET mutation carriers in Japanese patients with apparently sporadic medullary thyroid carcinoma: A single institution experience. *Auris Nasus Larynx* **43** 551–555. (<https://doi.org/10.1016/j.anl.2015.12.016>)
- Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, *et al.* 2011 Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. *Journal of Clinical Oncology* **29** 2660–2666. (<https://doi.org/10.1200/JCO.2010.32.4145>)
- Lairmore TC, Ball DW, Baylin SB & Wells SA Jr 1993 Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. *Annals of Surgery* **217** 595–601. (<https://doi.org/10.1097/0000658-199306000-00001>)
- Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, *et al.* 2010 Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. *Journal of Clinical Oncology* **28** 2323–2330. (<https://doi.org/10.1200/JCO.2009.25.0068>)
- Laure Giraudet A, Al Ghulzan A, Auperin A, Lebouilleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E & Schlumberger M 2008 Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. *European Journal of Endocrinology* **158** 239–246. (<https://doi.org/10.1530/EJE-07-0667>)
- Lips CJ, Landsvater RM, Hoppener JW, Geerdink RA, Blijham GH, Jansen-Schillhorn van Veen JM, Feldberg MA, van Gils AP, Hoogenboom H, Berends MJ, *et al.* 1995 From medical history and biochemical tests to presymptomatic treatment in a large MEN 2A family. *Journal of Internal Medicine* **238** 347–356. (<https://doi.org/10.1111/j.1365-2796.1995.tb01209.x>)
- Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, *et al.* 1996 The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families. *Clinical Endocrinology* **44** 213–220. (<https://doi.org/10.1046/j.1365-2265.1996.505292.x>)
- Modigliani E, Vasen HM, Raue K, Dralle H, Frilling A, Gheri RG, Brandi ML, Limbert E, Niederle B, Forgas L, *et al.* 1995 Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. *Journal of Internal Medicine* **238** 363–367. (<https://doi.org/10.1111/j.1365-2796.1995.tb01211.x>)
- Moley JF 2010 Medullary thyroid carcinoma: management of lymph node metastases. *Journal of the National Comprehensive Cancer Network* **8** 549–556. (<https://doi.org/10.6004/jnccn.2010.0042>)
- Moura MM, Cavaco BM, Pinto AE & Leite V 2011 High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. *Journal of Clinical Endocrinology and Metabolism* **96** E863–E868. (<https://doi.org/10.1210/jc.2010-1921>)
- Moura MM, Cavaco BM & Leite V 2015 RAS proto-oncogene in medullary thyroid carcinoma. *Endocrine-Related Cancer* **22** R235–R252. (<https://doi.org/10.1530/ERC-15-0070>)
- Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L, *et al.* 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. *Nature* **363** 458–460. (<https://doi.org/10.1038/363458a0>)
- Mulligan LM, Eng C, Attie T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A, *et al.* 1994 Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. *Human Molecular Genetics* **3** 2163–2167. (<https://doi.org/10.1093/hmg/3.12.2163>)
- Nakamura T, Ishizaka Y, Nagao M, Hara M & Ishikawa T 1994 Expression of the ret proto-oncogene product in human normal and neoplastic tissues of neural crest origin. *Journal of Pathology* **172** 255–260. (<https://doi.org/10.1002/path.1711720305>)
- Neumann HP, Vortmeyer A, Schmidt D, Werner M, Erlic Z, Cascon A, Bausch B, Januszewicz A & Eng C 2007 Evidence of MEN-2 in the original description of classic pheochromocytoma. *New England Journal of Medicine* **357** 1311–1315. (<https://doi.org/10.1056/NEJMoa071407>)

- Nunziata V, Giannattasio R, Di Giovanni G, D'Armiento MR & Mancini M 1989 Hereditary localized pruritus in affected members of a kindred with multiple endocrine neoplasia type 2A (Sipple's syndrome). *Clinical Endocrinology* **30** 57–63. (<https://doi.org/10.1111/j.1365-2265.1989.tb03727.x>)
- Oliveira MN, Hemerly JP, Bastos AU, Tamanaha R, Latini FR, Camacho CP, Impellizzeri A, Maciel RM & Cerutti JM 2011 The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. *Thyroid* **21** 975–985. (<https://doi.org/10.1089/thy.2010.0190>)
- Pelizzo MR, Boschini IM, Bernante P, Toniato A, Piotto A, Pagetta C, Nibale O, Rampin L, Muzzio PC & Rubello D 2007 Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. *European Journal of Surgical Oncology* **33** 493–497. (<https://doi.org/10.1016/j.ejso.2006.10.021>)
- Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, *et al.* 2015 RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. *Oncotarget* **6** 33993–34003. (<https://doi.org/10.18632/oncotarget.4992>)
- Ravaud A, de la Fouchardiere C, Asselineau J, Delord JP, Do Cao C, Niccoli P, Rodien P, Klein M & Catargi B 2010 Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. *Oncologist* **15** 212–213. (<https://doi.org/10.1634/2009-0303>)
- Robinson BG, Paz-Ares L, Krebs A, Vasselli J & Haddad R 2010 Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **95** 2664–2671. (<https://doi.org/10.1210/jc.2009-2461>)
- Rodriguez JM, Balsalobre M, Ponce JL, Rios A, Torregrosa NM, Tebar J & Parrilla P 2008 Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. *World Journal of Surgery* **32** 2520–2526. (<https://doi.org/10.1007/s00268-008-9734-2>)
- Romei C, Cosci B, Renzini G, Bottici V, Molinaro E, Agate L, Passannanti P, Viola D, Biagini A, Basolo F, *et al.* 2011 RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). *Clinical Endocrinology* **74** 241–247. (<https://doi.org/10.1111/j.1365-2265.2010.03900.x>)
- Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I, Pasini B, Boccardi R, Lerone M, Kaariainen H, *et al.* 1994 Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. *Nature* **367** 377–378. (<https://doi.org/10.1038/367377a0>)
- Rothberg AE, Raymond VM, Gruber SB & Sisson J 2009 Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. *Thyroid* **19** 651–655. (<https://doi.org/10.1089/thy.2009.0021>)
- Scapinelli JO, Ceolin L, Punaes MK, Dora JM & Maia AL 2016 MEN 2A-related cutaneous lichen amyloidosis: report of three kindred and systematic literature review of clinical, biochemical and molecular characteristics. *Familial Cancer* **15** 625–633. (<https://doi.org/10.1007/s10689-016-9892-6>)
- Scherubl H, Raue F & Ziegler R 1990 Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. *Journal of Cancer Research and Clinical Oncology* **116** 21–23. (<https://doi.org/10.1007/BF01612635>)
- Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, *et al.* 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. *Journal of Clinical Oncology* **27** 3794–3801. (<https://doi.org/10.1200/JCO.2008.18.7815>)
- Scholten A, Valk GD, Ulfman D, Borel Rinkes IH & Vriens MR 2011 Unilateral subtotal adrenalectomy for pheochromocytoma in multiple endocrine neoplasia type 2 patients: a feasible surgical strategy. *Annals of Surgery* **254** 1022–1027. (<https://doi.org/10.1097/SLA.0b013e318237480c>)
- Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S & Schlumberger M 2003 Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **88** 2070–2075. (<https://doi.org/10.1210/jc.2002-021713>)
- Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A, Aronson DC, Tan-Sindhunata G, Brouwers-Smalbraak GJ, Maas SM, *et al.* 1998 Oncological implications of RET gene mutations in Hirschsprung's disease. *Gut* **43** 542–547. (<https://doi.org/10.1136/gut.43.4.542>)
- Sipple J 1961 The association of pheochromocytoma and thyroid cancer. *American Journal of Medicine* **31** 163–166. ([https://doi.org/10.1016/0002-9343\(61\)90234-0](https://doi.org/10.1016/0002-9343(61)90234-0))
- Sipple JH 1984 Multiple endocrine neoplasia type 2 syndromes: historical perspectives. *Henry Ford Hospital Medical Journal* **32** 219–221.
- Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK & Wells SA Jr 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. *New England Journal of Medicine* **353** 1105–1113. (<https://doi.org/10.1056/NEJMoa043999>)
- Steiner AL, Goodman AD & Powers SR 1968 Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. *Medicine* **47** 371–409. (<https://doi.org/10.1097/00005792-196809000-00001>)
- Telenius-Berg M, Berg B, Hamberger B, Tibblin S, Tisell LE, Ysander L & Welanders G 1984 Impact of screening on prognosis in the multiple endocrine neoplasia type 2 syndromes: natural history and treatment results in 105 patients. *Henry Ford Hospital Medical Journal* **32** 225–231.
- Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, *et al.* 2014 Thyroid carcinoma, version 2.2014. *Journal of the National Comprehensive Cancer Network* **12** 1671–1680. (<https://doi.org/10.6004/jnccn.2014.0169>)
- Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D, Gangi E & Beck-Peccoz P 2003 Frequent association between MEN 2A and cutaneous lichen amyloidosis. *Clinical Endocrinology* **59** 156–161. (<https://doi.org/10.1046/j.1365-2265.2003.01782.x>)
- Weber T, Schilling T, Frank-Raue K, Colombo-Benkmann M, Hinz U, Ziegler R & Klar E 2001 Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. *Surgery* **130** 1044–1049. (<https://doi.org/10.1067/msy.2001.118380a>)
- Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J & Schlumberger M 2010 Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. *Journal of Clinical Oncology* **28** 767–772. (<https://doi.org/10.1200/JCO.2009.23.6604>)
- Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, *et al.* 2012 Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *Journal of Clinical Oncology* **30** 134–141. (<https://doi.org/10.1200/JCO.2011.35.5040>)
- Wells SA Jr, Pacini F, Robinson BG & Santoro M 2013 Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. *Journal of Clinical Endocrinology and Metabolism* **98** 3149–3164. (<https://doi.org/10.1210/jc.2013-1204>)
- Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, *et al.* 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid* **25** 567–610. (<https://doi.org/10.1089/thy.2014.0335>)

- Wermer P 1954 Genetic aspects of adenomatosis of endocrine glands. *American Journal of Medicine* **16** 363–371. ([https://doi.org/10.1016/0002-9343\(54\)90353-8](https://doi.org/10.1016/0002-9343(54)90353-8))
- Williams ED & Pollock DJ 1966 Multiple mucosal neuromata with endocrine tumours: a syndrome allied to von Recklinghausen's disease. *Journal of Pathology and Bacteriology* **91** 71–80. (<https://doi.org/10.1002/path.1700910109>)
- Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB & McGuire WP 3rd 1994 Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. *Cancer* **73** 432–436. ([https://doi.org/10.1002/1097-0142\(19940115\)73:2<432::AID-CNCR2820730231>3.0.CO;2-K](https://doi.org/10.1002/1097-0142(19940115)73:2<432::AID-CNCR2820730231>3.0.CO;2-K))
- Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F, Cancilla B, *et al.* 2011 Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Molecular Cancer Therapeutics* **10** 2298–2308. (<https://doi.org/10.1158/1535-7163.MCT-11-0264>)
- Zenaty D, Aigrain Y, Peuchmaur M, Philippe-Chomette P, Baumann C, Cornelis F, Hugot JP, Chevenne D, Barbu V, Guillausseau PJ, *et al.* 2009 Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. *European Journal of Endocrinology* **160** 807–813. (<https://doi.org/10.1530/EJE-08-0854>)

Received in final form 7 September 2017

Accepted 6 November 2017

Accepted preprint published online 15 November 2017